Literature DB >> 27638678

18F-FDG PET/CT Volumetric Parameters are Associated with Tumor Grade and Metastasis in Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease.

Kei Satoh1,2, Samira M Sadowski1, William Dieckmann3, Martha Quezado4, Naris Nilubol1, Electron Kebebew1, Dhaval Patel5.   

Abstract

BACKGROUND: Approximately 8-17 % of patients with von Hippel-Lindau (VHL) syndrome develop pancreatic neuroendocrine tumors (PNETs), with 11-20 % developing metastases. Tumor grade is predictive of prognosis.
OBJECTIVE: The aim of this study was to determine if preoperative metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were associated with metastatic disease and tumor grade.
METHODS: Sixty-two patients with VHL-associated PNETs prospectively underwent 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT). MTV, TLG, and maximum standardized uptake value (SUVmax) were measured using a semi-automatic method. Surgically resected PNETs were classified according to 2010 World Health Organization tumor grade classification. MTV, TLG, and SUVmax were analyzed by metastatic disease and tumor grade using the Mann-Whitney test.
RESULTS: A total of 88 PNETs were identified by CT and 18F-FDG PET/CT, 10 of which were non-FDG-avid. Histologic grading was available for 20 surgical patients. Patients with metastatic PNETs had a higher TLG (median 25.9 vs. 7.7 mean SUV [SUVmean]*mL; p = 0.0092) compared with patients without metastasis, while patients with grade 2 PNETs had a higher MTV (median 6.9 vs. 2.6 mL; p = 0.034) and TLG (median 41.2 vs. 13.1 SUVmean*mL; p = 0.0035) compared with patients with grade 1 PNETs. No difference in tumor size or SUVmax was observed between the groups.
CONCLUSIONS: Patients with metastatic PNETs have a higher TLG compared with patients without metastasis. Grade 2 PNETs have a higher MTV and TLG compared with grade 1 PNETs. Tumor size and SUVmax were not associated with grade. Volumetric parameters on 18F-FDG PET/CT may be useful in detecting higher grade PNETs with a higher malignant potential that may need surgical intervention.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27638678     DOI: 10.1245/s10434-016-5541-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

Review 1.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 2.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

3.  Pancreatic neuroendocrine neoplasms at magnetic resonance imaging: comparison between grade 3 and grade 1/2 tumors.

Authors:  Chuangen Guo; Xiao Chen; Wenbo Xiao; Qidong Wang; Ke Sun; Zhongqiu Wang
Journal:  Onco Targets Ther       Date:  2017-03-07       Impact factor: 4.147

4.  Two-stage resection of a bilateral pheochromocytoma and pancreatic neuroendocrine tumor in a patient with von Hippel-Lindau disease: A case report.

Authors:  Yutaka Endo; Minoru Kitago; Akira Miyajima; Isao Kurihara; Kaori Kameyama; Masahiro Shinoda; Hiroshi Yagi; Yuta Abe; Taizo Hibi; Chisato Takagi; Yutaka Nakano; Wataru Koizumi; Osamu Itano; Yuko Kitagawa
Journal:  Int J Surg Case Rep       Date:  2018-02-16

Review 5.  18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of clinically node-negative non-small cell lung cancer.

Authors:  Yusuke Takahashi; Shigeki Suzuki; Noriyuki Matsutani; Masafumi Kawamura
Journal:  Thorac Cancer       Date:  2019-01-21       Impact factor: 3.500

6.  Clinical presentation, genotype-phenotype correlations, and outcome of pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome.

Authors:  F Penitenti; L Landoni; M Scardoni; M L Piredda; S Cingarlini; A Scarpa; M D'Onofrio; D Girelli; M V Davi
Journal:  Endocrine       Date:  2021-05-25       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.